Yao-Wen Cheng1, Dana Alhaffar1, Srishti Saha2, Sahil Khanna2, Matthew Bohm1, Emmalee Phelps1, Marwan Ghabril1, Eric Orman1, Sagi Sashidhar1, Nicholas Rogers1, Huiping Xu3, Alexander Khoruts4, Byron Vaughn4, Dina Kao5, Karen Wong5, Giovanni Cammarota6, Gianluca Ianiro6, Tanvi Dhere7, Colleen S Kraft8, Nirja Mehta9, Michael H Woodworth9, Jessica R Allegretti10, Lotem Nativ10, Jenna Marcus10, Najwa El-Nachef11, Monika Fischer12. 1. Division of Gastroenterology, Indiana University School of Medicine, Indianapolis, Indiana. 2. Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. 3. Department of Biostatistics, The Richard M. Fairbanks School of Public Health and School of Medicine, Indiana University, Indianapolis, Indiana. 4. Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, Minnesota. 5. Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. 6. Digestive Disease Center, Gastroenterology and Oncology Area, Fondazione Policlinico Universitario "A. Gemelli", Universita Cattolica del Sacro Cuore, Rome, Italy. 7. Division of Digestive Diseases, Department of Medicine. 8. Division of Infectious Diseases, Department of Medicine; Department of Pathology, Emory University, Atlanta, Georgia. 9. Division of Infectious Diseases, Department of Medicine. 10. Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 11. Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, California. 12. Division of Gastroenterology, Indiana University School of Medicine, Indianapolis, Indiana. Electronic address: mofische@iu.edu.
Abstract
BACKGROUND & AIMS: Clostridioides difficile infection (CDI) harms a large proportion of patients with cirrhosis. Fecal microbiota transplantation (FMT) is recommended for recurrent CDI, but its effects in patients with cirrhosis have not been established. We performed a multicenter observational study to evaluate the efficacy and safety of FMT for CDI in patients with cirrhosis. METHODS: We performed a retrospective study of 63 adults with cirrhosis (median model for end-stage liver disease score, 14.5; 24 patients with decompensated cirrhosis) who underwent FMT for CDI from January 2012 through November 2018 at 8 academic centers in the United States, Canada, and Italy. We collected data on patient demographics and characteristics of cirrhosis, CDI, and FMT from medical records and compared differences among patients with different severities of cirrhosis, and FMT successes vs failures at the 8-week follow-up evaluation. We also obtained data on adverse events (AEs) and severe AEs within 12 weeks of FMT. RESULTS: Patients underwent FMT for recurrent CDI (55 of 63; 87.3%), severe CDI (6 of 63; 9.5%), or fulminant CDI (2 of 63; 3.2%) primarily via colonoscopy (59 of 63; 93.7%) as outpatients (47 of 63; 76.8%). FMT success was achieved for 54 patients (85.7%). Among FMT failures, a higher proportion used non-CDI antibiotics at the time of FMT (44.4% vs 5.6%; P < .001), had Child-Pugh scores of B or C (100% vs 37.7%; P < .001), used probiotics (77.8% vs 24.1%; P = .003), had pseudomembranes (22.2% vs 0; P = .018), and underwent FMT as inpatients (45.5% vs 19%; P = .039), compared with FMT successes. In multivariable analysis, use of non-CDI antibiotics at the time of FMT (odds ratio, 17.43; 95% CI, 2.00-152.03; P = .01) and use of probiotics (odds ratio, 11.9; 95% CI, 1.81-78.3; P = .01) were associated with a greater risk of FMT failure. FMT-related AEs occurred in 33.3% of patients (21 of 63)-most were self-limited abdominal cramps or diarrhea. There were only 5 severe AEs that possibly were related to FMT; none involved infection or death. CONCLUSIONS: In a retrospective study, we found FMT to be safe and effective for the treatment of CDI in patients with cirrhosis.
BACKGROUND & AIMS: Clostridioides difficile infection (CDI) harms a large proportion of patients with cirrhosis. Fecal microbiota transplantation (FMT) is recommended for recurrent CDI, but its effects in patients with cirrhosis have not been established. We performed a multicenter observational study to evaluate the efficacy and safety of FMT for CDI in patients with cirrhosis. METHODS: We performed a retrospective study of 63 adults with cirrhosis (median model for end-stage liver disease score, 14.5; 24 patients with decompensated cirrhosis) who underwent FMT for CDI from January 2012 through November 2018 at 8 academic centers in the United States, Canada, and Italy. We collected data on patient demographics and characteristics of cirrhosis, CDI, and FMT from medical records and compared differences among patients with different severities of cirrhosis, and FMT successes vs failures at the 8-week follow-up evaluation. We also obtained data on adverse events (AEs) and severe AEs within 12 weeks of FMT. RESULTS: Patients underwent FMT for recurrent CDI (55 of 63; 87.3%), severe CDI (6 of 63; 9.5%), or fulminant CDI (2 of 63; 3.2%) primarily via colonoscopy (59 of 63; 93.7%) as outpatients (47 of 63; 76.8%). FMT success was achieved for 54 patients (85.7%). Among FMT failures, a higher proportion used non-CDI antibiotics at the time of FMT (44.4% vs 5.6%; P < .001), had Child-Pugh scores of B or C (100% vs 37.7%; P < .001), used probiotics (77.8% vs 24.1%; P = .003), had pseudomembranes (22.2% vs 0; P = .018), and underwent FMT as inpatients (45.5% vs 19%; P = .039), compared with FMT successes. In multivariable analysis, use of non-CDI antibiotics at the time of FMT (odds ratio, 17.43; 95% CI, 2.00-152.03; P = .01) and use of probiotics (odds ratio, 11.9; 95% CI, 1.81-78.3; P = .01) were associated with a greater risk of FMT failure. FMT-related AEs occurred in 33.3% of patients (21 of 63)-most were self-limited abdominal cramps or diarrhea. There were only 5 severe AEs that possibly were related to FMT; none involved infection or death. CONCLUSIONS: In a retrospective study, we found FMT to be safe and effective for the treatment of CDI in patients with cirrhosis.
Authors: Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun Journal: Am J Gastroenterol Date: 2013-02-26 Impact factor: 10.864
Authors: G Ianiro; L Masucci; G Quaranta; C Simonelli; L R Lopetuso; M Sanguinetti; A Gasbarrini; G Cammarota Journal: Aliment Pharmacol Ther Date: 2018-05-30 Impact factor: 8.171
Authors: Jasmohan S Bajaj; Nita H Salzman; Chathur Acharya; Richard K Sterling; Melanie B White; Edith A Gavis; Andrew Fagan; Michael Hayward; Mary L Holtz; Scott Matherly; Hannah Lee; Majdi Osman; Mohammad S Siddiqui; Michael Fuchs; Puneet Puri; Masoumeh Sikaroodi; Patrick M Gillevet Journal: Hepatology Date: 2019-06-18 Impact factor: 17.425
Authors: Jasmohan S Bajaj; Ashwin N Ananthakrishnan; Muhammad Hafeezullah; Yelena Zadvornova; Alexis Dye; Emily L McGinley; Kia Saeian; Douglas Heuman; Arun J Sanyal; Raymond G Hoffmann Journal: Am J Gastroenterol Date: 2009-10-20 Impact factor: 10.864
Authors: Jasmohan S Bajaj; Andrew Fagan; Edith A Gavis; Zain Kassam; Masoumeh Sikaroodi; Patrick M Gillevet Journal: Gastroenterology Date: 2019-01-18 Impact factor: 22.682
Authors: Zachariah DeFilipp; Patricia P Bloom; Mariam Torres Soto; Michael K Mansour; Mohamad R A Sater; Miriam H Huntley; Sarah Turbett; Raymond T Chung; Yi-Bin Chen; Elizabeth L Hohmann Journal: N Engl J Med Date: 2019-10-30 Impact factor: 91.245
Authors: Jasmohan S Bajaj; Amirhossein Shamsaddini; Andrew Fagan; Richard K Sterling; Edith Gavis; Alexander Khoruts; Michael Fuchs; Hannah Lee; Masoumeh Sikaroodi; Patrick M Gillevet Journal: Hepatol Commun Date: 2020-11-21
Authors: Patricia P Bloom; John Donlan; Mariam Torres Soto; Michael Daidone; Elizabeth Hohmann; Raymond T Chung Journal: Hepatol Commun Date: 2022-04-05